Skip to main content
. 2024 Sep 15;7:1149. doi: 10.1038/s42003-024-06865-4

Fig. 4. Validation of differential potency predictions.

Fig. 4

ad In vitro dose-response relationships of HCC1806-Par differentially potent compounds (n = 4 independent experiments) and e, f MDA-MB-231-Par differentially potent compounds (n = 4 independent experiments). 95% confidence intervals. g Relationship between the predicted and observed differences in IC50 values of tested compounds between HCC1806-Par and MDA-MB-231-Par cell lines. Two-sided t-test (n = 6 independent experiments).